.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
UBS
Mallinckrodt
QuintilesIMS
Cerilliant
Boehringer Ingelheim
AstraZeneca
Express Scripts
Queensland Health
Cantor Fitzgerald

Generated: December 15, 2017

DrugPatentWatch Database Preview

Valeant Bermuda Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT BERMUDA, and when can generic versions of VALEANT BERMUDA drugs launch?

VALEANT BERMUDA has eight approved drugs.

There are five US patents protecting VALEANT BERMUDA drugs.

There are eighty-eight patent family members on VALEANT BERMUDA drugs in thirty-six countries and twenty-four supplementary protection certificates in twelve countries.

Summary for Valeant Bermuda

International Patents:88
US Patents:5
Tradenames:7
Ingredients:7
NDAs:8
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Valeant BermudaBENZACLINbenzoyl peroxide; clindamycin phosphateGEL;TOPICAL050756-001Dec 21, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Valeant BermudaZOVIRAXacyclovirOINTMENT;TOPICAL018604-001Mar 29, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Valeant BermudaXERESEacyclovir; hydrocortisoneCREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Valeant BermudaDERMATOP E EMOLLIENTprednicarbateCREAM;TOPICAL020279-001Oct 29, 1993ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Valeant BermudaPENLACciclopiroxSOLUTION;TOPICAL021022-001Dec 17, 1999ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Valeant BermudaXERESEacyclovir; hydrocortisoneCREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Valeant BermudaBENZACLINbenzoyl peroxide; clindamycin phosphateGEL;TOPICAL050756-002Apr 20, 2007DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Valeant BermudaELIDELpimecrolimusCREAM;TOPICAL021302-001Dec 13, 2001RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Valeant BermudaRETIN-AtretinoinCREAM;TOPICAL017522-001Approved Prior to Jan 1, 1982AB1RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Valeant BermudaXERESEacyclovir; hydrocortisoneCREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Valeant Bermuda

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant BermudaZOVIRAXacyclovirOINTMENT;TOPICAL018604-001Mar 29, 1982► Subscribe► Subscribe
Valeant BermudaRETIN-AtretinoinCREAM;TOPICAL019049-001Sep 16, 1988► Subscribe► Subscribe
Valeant BermudaDERMATOP E EMOLLIENTprednicarbateCREAM;TOPICAL020279-001Oct 29, 1993► Subscribe► Subscribe
Valeant BermudaRETIN-AtretinoinCREAM;TOPICAL017522-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Valeant BermudaPENLACciclopiroxSOLUTION;TOPICAL021022-001Dec 17, 1999► Subscribe► Subscribe
Valeant BermudaRETIN-AtretinoinCREAM;TOPICAL017522-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Valeant BermudaRETIN-AtretinoinCREAM;TOPICAL019049-001Sep 16, 1988► Subscribe► Subscribe
Valeant BermudaXERESEacyclovir; hydrocortisoneCREAM;TOPICAL022436-001Jul 31, 2009► Subscribe► Subscribe
Valeant BermudaELIDELpimecrolimusCREAM;TOPICAL021302-001Dec 13, 2001► Subscribe► Subscribe
Valeant BermudaELIDELpimecrolimusCREAM;TOPICAL021302-001Dec 13, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Valeant Bermuda

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,337,324 Pharmaceutical combination► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Valeant Bermuda Drugs

Country Document Number Estimated Expiration
Portugal1131104► Subscribe
Japan5420583► Subscribe
Germany69721484► Subscribe
Denmark0876146► Subscribe
Austria421358► Subscribe
Israel125075► Subscribe
Czech Republic297841► Subscribe
JapanH11506417► Subscribe
European Patent Office0809498► Subscribe
Egypt23853► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Valeant Bermuda Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013025,C1304992Lithuania► SubscribePRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
C/GB11/054United Kingdom► SubscribePRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
2008000041Germany► SubscribePRODUCT NAME: ADAPALEN IN KOMBINATION MIT BENZOYLPEROXID; NAT. REGISTRATION NO/DATE: 67913.00.00 20080229; FIRST REGISTRATION: DAENEMARK 40440 20071218
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
00617Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
C/GB01/014United Kingdom► SubscribePRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018
C0042Belgium► SubscribePRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
1304992/01Switzerland► SubscribePRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
C/GB05/030United Kingdom► SubscribePRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
90049-3Sweden► SubscribePRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Queensland Health
AstraZeneca
Julphar
Daiichi Sankyo
Farmers Insurance
US Army
Boehringer Ingelheim
Argus Health
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot